1. The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens
- Author
-
Agata Blasiak, Anh T. L. Truong, Alexandria Remus, Lissa Hooi, Shirley Gek Kheng Seah, Peter Wang, De Hoe Chye, Angeline Pei Chiew Lim, Kim Tien Ng, Swee Teng Teo, Yee-Joo Tan, David Michael Allen, Louis Yi Ann Chai, Wee Joo Chng, Raymond T. P. Lin, David C. B. Lye, John Eu-Li Wong, Gek-Yen Gladys Tan, Conrad En Zuo Chan, Edward Kai-Hua Chow, and Dean Ho
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 live virus and Vero E6 assay with a quadratic optimization workflow. A starting pool of 12 candidate drugs developed in collaboration with a community of infectious disease clinicians was first narrowed down to a six-drug pool and then interrogated in 50 combination regimens at three dosing levels per drug, representing 729 possible combinations. IDentif.AI-x revealed EIDD-1931 to be a strong candidate upon which multiple drug combinations can be derived, and pinpointed a number of clinically actionable drug interactions, which were further reconfirmed in SARS-CoV-2 variants B.1.351 (Beta) and B.1.617.2 (Delta). IDentif.AI-x prioritized promising drug combinations for clinical translation and can be immediately adjusted and re-executed with a new pool of promising therapies in an actionable path towards rapidly optimizing combination therapy following pandemic emergence.
- Published
- 2022
- Full Text
- View/download PDF